Nephrology

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

Meta-analysis finds peritoneal and hemodialysis offer similar survival in ESRD.

Elevated neutrophil-to-lymphocyte ratio predicts early kidney decline in IgA nephropathy.

Post-transplant survival prediction algorithms can lower rates of donor discards.

Artificial Intelligence-Assisted Model Can Automate Diagnosis of Glomerular Nephritis.

Advanced CKD shows higher rates of certain ERCP complications but not post-ERCP pancreatitis compared with the general population.

Perceived behavioral control emerged as a predictor of immunosuppression adherence after kidney transplantation, pointing to practical intervention targets.

Among patients with primary hyperoxaluria and CKD, those with delayed CKD diagnosis were more likely to encounter greater healthcare burdens.

Stay updated with the latest healthcare breakthroughs, including FDA updates and phase 3 trial readouts, in this week's essential news roundup.

Final results from APPLAUSE-IgAN demonstrate iptacopan’s superiority versus placebo for slowing IgAN progression and will be used to support its full approval.

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

Increases in short-term kidney function decline were observed following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

An audio recap of the top 5 stories in healthcare news from the week of 9/28-10/04.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Barratt describes the evolving diagnostic and therapeutic landscape of IgAN and breaks down key recommendations from the new KDIGO guidelines.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

Check out renal FDA news, new KDIGO guidelines on IgAN and IgAV management, research about hypertensive kidney disease, and more.

Neuen is joined by Richard Pratley, MD, and Muthiah Vaduganathan, MD, MPH, to discuss the evolving landscape of CKM trial design.

The 2025 guideline updates previous recommendations made in the 2021 glomerular disease guideline based on recent therapeutic advances in IgAN.

An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.

The US Food and Drug Administration has approved bumetanide nasal spray for the treatment of edema in outpatient heart, liver, and kidney diseases.

Stay updated with the latest healthcare breakthroughs, including FDA news and the voluntary withdrawal of obeticholic acid, in this week's essential news roundup.

Upon further review of the sNDA, the Agency indicated an advisory committee for sparsentan in FSGS is no longer needed.